Analyze What Papers Actually Reported

Concise plan

Produce a reproducible, modular bioinformatics and statistics pipeline to QC, normalize, visualize, and meta-analyze Activation Induced Marker (AIM) flow cytometry/CyTOF datasets (including combined AIM+ICS and composite cAIM metrics), compute sensitivity/specificity and marker combinations, and produce publication-grade plots plus summary metrics for assay validation and cross-study comparison.

• Key refs: assay optimization and multi-marker AIM methods, combined AIM+ICS protocol, and composite cAIM scoring described in nonhuman primates (see citations below).

Comprehensive bioinformatics and analysis plan for AIM assays

Goal: deliver a reproducible pipeline that takes raw flow cytometry or CyTOF files and experimental design metadata and outputs rigorous QC, marker gating consistency checks, marker combination performance (sensitivity, specificity, background), composite cAIM metrics, visualization, and tables ready for publication and regulatory review.

Overview workflow (high level)

1. Data ingestion and metadata harmonization (FCS and design CSV)
2. Quality control and compensation verification
3. Automated gating and manual review (semi-supervised)
4. Compute AIM positive cell frequencies per marker pair and combined populations
5. Background subtraction and noise estimation
6. Normalisation across batches / instruments
7. Composite scoring (cAIM index and cAIM score) and statistical testing
8. Visualization and reporting (plotly interactive figures and publication PNGs)
9. Meta-analysis across experiments/studies with mixed-effects models

Why each step matters

Multi-marker AIM approaches are sensitive to stimulation timing, marker selection, and background; the foundational work recommends specific markers and protocols for CD4 and CD8 that permit sorting and downstream assays without intracellular staining, and combined AIM+ICS shows how to co-measure cytokines while preserving sensitivity—these method choices change the downstream data-processing needs and performance metrics, so the pipeline must encode those considerations explicitly

Key method references underpinning design decisions:

• Multi-marker AIM optimization methods (OX40 CD137 CD154 ICOS CD69), enabling viable cell sorting and downstream single-cell assays Multi marker AIM optimization
• Combined AIM plus ICS demonstrates marker selection effects (CD107a CD137 lower background for CD8) and sample handling tips (supernatant collection before transport inhibitors) valuable for pipeline assumptions Combined AIM ICS protocol
• Composite AIM (cAIM) defines aggregated indices for multiantigen summary scoring that streamline cross-antigen comparisons and preclinical-to-clinical translation cAIM composite metrics

Detailed stepwise bioinformatics plan

1 Data ingestion and metadata

• Inputs accepted: FCS 3.0/3.1 files (flow cytometry) and .txt or .csv CyTOF exports, plus an experiment manifest CSV containing sample ID, donor, timepoint, stimulation antigen, batch/instrument, viability dye channel name, compensation matrix path (if not embedded), and antibody panel map (channel to marker including clones and fluorochrome).
• Validate metadata using schema checks and fail-fast alerts if required fields are missing.

2 QC and pre-processing

• Automated per-file checks: event counts, viability fraction, doublet rate (FSC-H vs FSC-A), mean fluorescence intensity (MFI) shifts vs internal controls, saturation/overflow flags.
• Compensation matrix verification: compare embedded vs provided matrix; if missing, estimate from single-color controls with linear regression and warn on high cross-talk.
• Remove dead cells and doublets consistently across files using same gating heuristics; record removed event counts for audit.

3 Gating strategy (semi-automated)

• Primary gate sequence: lymphocyte clustering (FSC/SSC), singlets, live cells, CD3+ then CD4 vs CD8 subsets. For CyTOF adapt markers and arcsinh transform parameters.
• Use automated clustering and gating (FlowSOM or Phenograph) to suggest gates plus manual override JSON file for curated gold-standard gates when available.
• Store gates in standardized GatingML or RDS to enable reproducibility.

4 Compute AIM positive calls and combinations

• For each sample and antigen stimulus compute frequencies (percentage of parent) of cells positive for single AIM markers (e.g., OX40+, CD137+), marker pairs (OX40+CD137+), and multi-marker intersections or logical unions (markerA AND markerB; markerC OR markerD). Use consistent positivity thresholds defined per-run using negative controls (see background estimation below).
• Report counts and frequencies with bootstrap 95% confidence intervals.

5 Background estimation and limit of detection

• Estimate per-marker and per-marker-pair background from negative (DMSO) controls: compute median and robust measures (median absolute deviation). Define assay-specific positivity threshold e.g., median negative + X MAD where X chosen to control desired false positive rate; also compute empirical FDR using negative-control pool.
• When paired/replicate negatives exist, model background as hierarchical (sample nested within donor) for more accurate thresholds.

6 Normalization across batches and instruments

• Use control beads or reference samples to estimate per-channel scaling factors and apply linear scaling or quantile normalization as appropriate; for CyTOF use bead-based normalization tools.
• Implement Harmony or ComBat (empirical Bayes) style correction for non-linear or batch-structured covariates while preserving biological variation.

7 Composite scoring and cAIM metrics

• Implement cAIM index and cAIM score definitions as described in the composite AIM reference: normalize each antigen-marker frequency to its negative-control SD, sum or weighted-sum across antigens, and compute sample-level cAIM index; also compute cAIM score as an effect-size standardized metric between stimulated and negative for each donor cAIM composite metrics
• Provide options for weighting antigens by biological priors (e.g., immunodominance) or data-driven weights (PCA loadings or random forest feature importance).

8 Statistical testing and effect sizes

• For within-donor stimulated vs negative: use paired tests (Wilcoxon signed-rank or paired t where normal) and compute Cohen d for effect size; for multiple antigens adjust p-values with Benjamini-Hochberg.
• For group-level comparisons across cohorts or treatments: fit mixed-effects models (donor as random effect) to account for repeated measures and batch covariates; report marginal and conditional R2 and model diagnostics.

9 Performance evaluation for marker combinations

• Compute sensitivity, specificity, positive predictive value, negative predictive value for single markers, pairs, and chosen logical combinations using known positives/negatives (e.g., PHA or known antigen responders). Produce ROC curves and AUCs; include empirical stratified bootstrap CIs.
• Use decision-curve analysis when clinical thresholds are relevant.

10 Visualization and reporting

• Interactive plotly figures: per-marker background violin + jitter plots; paired scatter of stimulated vs negative; ROC curves with confidence bands; heatmaps of cAIM index per antigen; UMAP/TSNE for high-dim CyTOF gating overlays.
• Export static publication PNGs and a comprehensive HTML report with methods, QC metrics and tables.

11 Reproducibility, provenance, and audit

• Track versions of code, package environment (conda), and store checksums of raw FCS files. Export full run manifest JSON documenting parameters used (thresholds, normalization factors, gating overrides) to enable audit/re-run.

Software ecosystem and preferred libraries

Implement primarily in Python with optional R modules for established cytometry libraries. Recommended packages:

• Python core: pandas numpy scipy statsmodels scikit-learn matplotlib seaborn plotly anndata
• Flow/cytometry: flowkit (python), CytoPy, FlowCytometryTools; for R interoperability use flowCore flowWorkspace openCyto (via reticulate or R subprocess)
• Clustering/dimensionality: FlowSOM (R) or Phenograph (python), UMAP-learn
• Batch correction: pycombat/harmony wrappers
• Report automation: Jupyter Notebooks -> nbconvert to HTML or Rmarkdown

Data model and outputs

• Primary outputs: per-sample per-antigen frequency table with CI, per-sample cAIM index and cAIM score, QC summary table, per-marker background metrics, ROC and AUC summary table, model fit reports (mixed-effects), interactive HTML report.
• Standardize outputs to a results CSV and JSON plus an archived results folder including plots and raw intermediate matrices.

Validation plan and acceptance criteria

• Analytical validation: verify limits of detection using negative controls and spiked-in responders; acceptable false positive rate decision (e.g., FPR <5% across negatives) and sensitivity benchmark against PHA or known positives.
• Inter-run reproducibility: compute intraclass correlation (ICC) across replicated controls; target ICC >0.8 for primary cAIM metrics.
• Cross-platform concordance: when same samples measured on two instruments, compute Passing-Bablok regression and Bland-Altman plots to assess bias; define acceptable proportional bias thresholds per regulatory guidance.

Specific statistical recipes and equations

Background threshold: Thresholdmarker = median(negatives) + k * MAD(negatives) where MAD = median absolute deviation and k chosen to approximate desired alpha (e.g., k=3 approximates robust 3-sigma).

cAIM index (example): cAIMindex = sum over antigens of ((freqstim_antigen - freqneg_antigen) / sdneg_antigen) / sqrt(number antigens) — this standardizes antigen responses and aggregates them as an effect-size like score cAIM composite metrics

Practical recommendations and pitfalls

• Marker selection: for CD8 use CD107a CD137 to reduce background when possible as empirically observed Combined AIM ICS protocol
• Supernatant handling: collecting half supernatant before adding protein transport inhibitors did not significantly change detection in combined AIM+ICS studies — important when measuring secreted cytokines alongside AIM Combined AIM ICS protocol
• Batch and instrument variance often exceed biological signals for small antigen effects — include reference samples and bead controls across runs.

Deliverables and timeline (example for a 6 week sprint)

• Week 1: ingest sample set, metadata QC, and implement basic single-file QC checks
• Week 2: gating pipeline, automated gate suggestions, and manual gate reconciliation
• Week 3: compute AIM frequencies, background estimation, and thresholds; implement cAIM metrics
• Week 4: normalization and batch correction module; initial ROC and marker combination analysis
• Week 5: mixed-effects modeling, reproducibility tests, and produce interactive plots
• Week 6: final report HTML, static figure export, and code packaging with environment spec

Example output visualizations (interactive)

Validation and evidence synthesis

Use reported AIM optimization literature and combined AIM+ICS studies to benchmark thresholds and expected signal sizes; adoption of cAIM composite metrics is supported by recent preclinical work enabling cross-antigen aggregation and smaller-sample interpretability Multi marker AIM optimizationCombined AIM ICS protocolcAIM composite metrics

Limitations and blind spots

• Marker background and low-frequency antigen responses can be confounded by sample handling, donor variability, or batch effects; small effect sizes require larger cohorts or repeated measures.
• Composite metrics (cAIM) reduce dimensional complexity but risk masking antigen-specific outlier responses — always supply per-antigen summaries alongside composite scores.
• Cross-lab comparisons require strict harmonization of antibody clones, fluorochromes, stimulation conditions and timepoints; differences limit direct pooling without careful harmonization.

Next steps and optional extensions

• Integrate TCR sequencing or single-cell RNA+protein (CITE-seq) downstream from sorted AIM populations for clonotype and transcriptional profiling.
• Adapt pipeline to mass cytometry (CyTOF) high-dimensional AIM panels and integrate debarcoding steps.
• Build a reference atlas of negative control distributions to enable standardized thresholds across labs.

Run AI biology analysis

If you want this plan executed on your raw files and a reproducible report produced, run the AI Bioinformatics agent below (it will ingest your FCS/CyTOF files, metadata manifest, and produce results):

References used in planning (select)

• Multi marker AIM optimization
• Combined AIM ICS protocol
• cAIM composite metrics

Confidence note: design choices are evidence-aligned to published AIM optimization and composite AIM methodologies; empirical parameter tuning (MAD k value, weighting schemes) must be calibrated per-dataset. What would change conclusions: consistent large batch effects, missing negative controls, or marker clone differences across labs would require re-derivation of thresholds and possibly different marker choices.